| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/11/1998 | WO1998024437A1 Pyrazoles as human non-pancreatic secretory phospholipase a2 inhibitors |
| 06/11/1998 | WO1998024436A2 Gel formulations for topical drug delivery |
| 06/11/1998 | WO1998024435A1 Use of 2-(4-methoxyphenyl)-pyrazolo(4,3-c)quinolin-3-one in the manufacture of a medicament for enhancing cognition |
| 06/11/1998 | WO1998024434A1 Novel therapeutic application of a thienycyclohexylamine derivative |
| 06/11/1998 | WO1998024433A1 Application of thalidomide to the treatment of parkinson's disease and parkisonian syndromes |
| 06/11/1998 | WO1998024432A2 Use of indolinone compounds as modulators of protein kinases |
| 06/11/1998 | WO1998024430A1 Pharmaceutical compositions containing n-sulphonyl indolin derivatives |
| 06/11/1998 | WO1998024429A1 Synthetic techniques and intermediates for polyhydroxy, dienyllactones and mimics thereof |
| 06/11/1998 | WO1998024428A1 Long-acting local anesthetics |
| 06/11/1998 | WO1998024427A2 Compositions and methods for treating or preventing inflammatory diseases |
| 06/11/1998 | WO1998024426A1 Zinc-based antiirritant creams |
| 06/11/1998 | WO1998024425A1 Cisplatinum comprising pharmaceutical |
| 06/11/1998 | WO1998024424A1 Cisplatinum comprising pharmaceutical |
| 06/11/1998 | WO1998024423A1 Felbinac-containing patch |
| 06/11/1998 | WO1998024422A2 Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein |
| 06/11/1998 | WO1998024421A2 Use of dextrin sulphate for the treatment of highly vascular tumours |
| 06/11/1998 | WO1998024418A1 Medicinal composition |
| 06/11/1998 | WO1998024416A1 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(ii) complexes |
| 06/11/1998 | WO1998024411A2 Method for oral administration of buspirone |
| 06/11/1998 | WO1998024403A1 Barrier to plaque formation |
| 06/11/1998 | WO1998024397A2 Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense |
| 06/11/1998 | WO1998024396A2 Methods of treating mental diseases, inflammation and pain |
| 06/11/1998 | WO1998024381A1 Method of improving outcome of cardiopulmonary bypass surgery |
| 06/11/1998 | WO1998016186A3 Monocyclic l-nucleosides, analogs and uses thereof |
| 06/11/1998 | WO1998015263A3 A method for producing a microparticle |
| 06/11/1998 | WO1998012910A3 Novel CREBa isoform |
| 06/11/1998 | WO1998011091A3 Tricyclic compounds useful for inhibition of farnesyl protein transferase |
| 06/11/1998 | CA2607067A1 Compositions and methods for treating or preventing inflammatory diseases |
| 06/11/1998 | CA2274584A1 Tissue specific and target rna-specific ribozymes as antimicrobial therapeutics against microbial pathogens |
| 06/11/1998 | CA2274461A1 Reactive oxygen intermediates containing compounds effective in inducing cell differentiation of malignant cells such as leukemia |
| 06/11/1998 | CA2274120A1 Plaster containing felbinac |
| 06/11/1998 | CA2274048A1 Pyrazoles as human non-pancreatic secretory phospholipase a2 inhibitors |
| 06/11/1998 | CA2274023A1 Use of 7-alkylidene cephalosporins to inhibit elastase activity |
| 06/11/1998 | CA2274019A1 Phenyl glyoxamides as spla2 inhibitors |
| 06/11/1998 | CA2274002A1 Wound healing and treatment of fibrosis |
| 06/11/1998 | CA2273995A1 Phenyl acetamides as spla2 inhibitors |
| 06/11/1998 | CA2273990A1 Pharmaceutical compositions containing n-sulphonyl indolin derivatives |
| 06/11/1998 | CA2273900A1 Barrier to plaque formation |
| 06/11/1998 | CA2273881A1 Synthetic techniques and intermediates for polyhydroxy, dienyllactones and mimics thereof |
| 06/11/1998 | CA2273856A1 Use of nk-1 receptor antagonists for treating bipolar disorders |
| 06/11/1998 | CA2273853A1 Use of nk-1 receptor antagonists for treating cognitive disorders |
| 06/11/1998 | CA2273850A1 Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
| 06/11/1998 | CA2273846A1 Use of dextrin sulphate for the treatment of highly vascular tumours |
| 06/11/1998 | CA2273810A1 Use of nk-1 receptor antagonists for treating major depressive disorders |
| 06/11/1998 | CA2273809A1 Use of nk-1 receptor antagonists for treating movement disorders |
| 06/11/1998 | CA2273807A1 Use of nk-1 receptor antagonists for treating schizophrenic disorders |
| 06/11/1998 | CA2273806A1 Use of nk-1 receptor antagonists for treating substance use disorders |
| 06/11/1998 | CA2273800A1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| 06/11/1998 | CA2273786A1 Use of nk-1 receptor antagonists for treating stress disorders |
| 06/11/1998 | CA2273785A1 Use of nk-1 receptor antagonists for treating severe anxiety disorders |
| 06/11/1998 | CA2273497A1 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(ii) complexes |
| 06/11/1998 | CA2273364A1 Substituted benzamide derivatives and pharmaceutical compositions containing them |
| 06/11/1998 | CA2273351A1 Use of nk-1 receptor antagonists for treating sexual dysfunction |
| 06/11/1998 | CA2273203A1 Antisense inhibition of human adhesion molecules |
| 06/11/1998 | CA2273192A1 Inactivation of hiv co-receptors as therapy for hiv infection |
| 06/11/1998 | CA2273184A1 Alarm related peptides and nucleic acids and diagnosis using them |
| 06/11/1998 | CA2273002A1 Immunotherapeutic imides/amides as pde iv and tnf inhibitors |
| 06/11/1998 | CA2272891A1 Method of preventing neurodegeneration and cognitive dysfunction using 17.alpha.-dihydroequilenin |
| 06/11/1998 | CA2272604A1 Topical preparation for introducing peptidaceous pharmacons in living organisms |
| 06/11/1998 | CA2272548A1 Serine protease inhibitors |
| 06/11/1998 | CA2272470A1 Use of 2-(4-methoxyphenyl)-pyrazolo(4,3-c)quinolin-3-one in the manufacture of a medicament for enhancing cognition |
| 06/11/1998 | CA2272330A1 Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds |
| 06/11/1998 | CA2272148A1 Vitamin d3 derivatives |
| 06/11/1998 | CA2271072A1 1,4-diazabicyclo [2.2.2] oct-2-ylmethyl derivatives, their preparation and therapeutic application |
| 06/11/1998 | CA2269674A1 Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein |
| 06/11/1998 | CA2245699A1 Substituted sulfonic acid n-¬(aminoiminomethyl)phenylalkyl}-azaheterocyclamide compounds |
| 06/11/1998 | CA2243083A1 Low dosage of budesonide |
| 06/11/1998 | CA2224334A1 Self-enhancing, pharmacologically controllable expression systems |
| 06/10/1998 | EP0846704A2 Highly fermentable resistant starch |
| 06/10/1998 | EP0846698A1 Dermatologic external preparation |
| 06/10/1998 | EP0846697A1 Process for the preparation of erythromycin derivatives |
| 06/10/1998 | EP0846695A1 Process for the preparation of new intermediates useful in the synthesis of cephalosporins |
| 06/10/1998 | EP0846694A1 Morphinan derivative and its pharmaceutical applications |
| 06/10/1998 | EP0846693A1 N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same |
| 06/10/1998 | EP0846689A1 Benzimidazole compounds |
| 06/10/1998 | EP0846688A1 New imidazoline derivatives having affinity for the imidazoline receptor |
| 06/10/1998 | EP0846687A1 Pyrazoles as human non-pancreatic secretory phospholipase A2 inhibitors |
| 06/10/1998 | EP0846686A1 1-Phenyl-pyrazol derivatives and their use as parasiticidal agents |
| 06/10/1998 | EP0846685A1 3-Hydroxypyridine-2-carboxylic acid amide esters, their preparation and their use as medicaments |
| 06/10/1998 | EP0846465A1 Remedy for anxiety neurosis |
| 06/10/1998 | EP0846464A2 Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia |
| 06/10/1998 | EP0846463A2 Active substance containing plaster |
| 06/10/1998 | EP0846462A1 Cosmetic composition in the form of a foaming transparent gel |
| 06/10/1998 | EP0846422A1 Anti-regurgitation infant formula |
| 06/10/1998 | EP0846265A1 Methods for g protein coupled receptor activity screening |
| 06/10/1998 | EP0846181A1 cDNA CORRESPONDING TO THE ANTIGENOME OF NONSEGMENTED NEGATIVE STRAND RNA VIRUSES, AND PROCESS FOR THE PRODUCTION OF SUCH VIRUSES ENCODING ADDITIONAL ANTIGENICALLY ACTIVE PROTEINS |
| 06/10/1998 | EP0846178A1 Allergen-xcd32 fusion proteins |
| 06/10/1998 | EP0846173A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 06/10/1998 | EP0846170A1 Modified protein kinase a-specific oligonucleotides and methods of their use |
| 06/10/1998 | EP0846128A2 Antimicrobial cationic peptides and methods of screening for the same |
| 06/10/1998 | EP0846120A1 Low molecular weight bicyclic-area type thrombin inhibitors |
| 06/10/1998 | EP0846119A1 Thienopyrimidine derivatives, their production and use |
| 06/10/1998 | EP0846118A1 Cyclic gmp-specific phosphodiesterase inhibitors |
| 06/10/1998 | EP0846116A1 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists |
| 06/10/1998 | EP0846115A1 New cyclic guanidines, process for preparing the same and medicaments |
| 06/10/1998 | EP0846114A1 3-pyridyloxyalkyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| 06/10/1998 | EP0846110A1 Thf-containing sulfonamide inhibitors of aspartyl protease |
| 06/10/1998 | EP0846108A1 Amino-substituted thiadiazoles, pyrimidines, triazines or triazoles useful as ctf receptor antagonists |
| 06/10/1998 | EP0846001A1 Control of cd44 gene expression for therapeutic use |
| 06/10/1998 | EP0845996A1 Treatment of nocturnal polyuria using an ace inhibitor in combination with a diuretic |